The stock is very cheap given that OGXI has two P3 trials recruiting with the same end points as the P2 trials. 2012 ASCO is going to be very interesting. Investors should get a look at some early P3 trial data, most likely from the pain pap trial.
I agree with box buy the dips on this one, its a no brainer
thanks for the post and the article. pre approval price of OGXI will hopefully also be influenced by news about 427 moving into Phase III. don't know exact timing about 427 but it would be nice if discussed at ASCO 2012. repeat of 2009 ASCO maybe.